Turtlemint Fintech invests ₹149.51 crore in subsidiary TIB
- Turtlemint Fintech invested ₹149.51 crore in subsidiary TIB on October 14, 2026
- Investment made via rights issue subscription to strengthen working capital
- TIB turnover grew from ₹5,050.54 million in FY24 to ₹10,721.99 million in FY26
- Capital injection represents approximately 8.5% of TIB's current net worth

*this image is generated using AI for illustrative purposes only.
Turtlemint Fintech Solutions Limited invested ₹149.51 crore in its wholly owned subsidiary, Turtlemint Insurance Broking Services Private Limited (TIB), through a rights issue subscription on October 14, 2026. The infusion aims to strengthen TIB's working capital and support lease obligations.
The Board of Directors approved the investment at its meeting held on October 14, 2026. The company subscribed to up to 8,41,715 equity shares of TIB with a face value of ₹10 each. The issue price was set at ₹1,776.27 per share, which includes a premium of ₹1,766.27 per share.
Strategic Rationale and Subsidiary Profile
The investment is designated to enable TIB to meet working capital requirements, including lease payments for its existing properties. This action aligns with the objects disclosed in the company's Initial Public Offer prospectus. As TIB is a wholly owned subsidiary, there is no change in the shareholding percentage held by Turtlemint Fintech Solutions following this transaction.
TIB operates as a Composite Insurance Broker registered with the Insurance Regulatory and Development Authority of India (IRDAI). The entity handles general insurance, life insurance, and reinsurance for retail segments such as motor, health, and general policies. Incorporated on October 24, 2013, TIB has demonstrated significant growth in its top line over the past three fiscal years.
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Turnover (₹ million) | 5,050.54 | 6,745.24 | 10,721.99 |
What the Numbers Show
A comparison of TIB's financial trajectory reveals a sharp acceleration in revenue generation alongside the capital infusion. Turnover grew from ₹5,050.54 million in FY24 to ₹10,721.99 million in FY26, indicating a more than doubling of business volume in two years. Despite this substantial increase in turnover, the net worth as of March 31, 2026, stood at ₹1,758.63 million. The ₹149.51 crore investment represents approximately 8.5% of the subsidiary's current net worth, suggesting a targeted capital injection to support operational scaling rather than a recapitalization of distressed assets. The post-infusion paid-up capital of TIB is reported at ₹168.31 lakh, reflecting the updated equity base after the rights issue subscription.
Historical Stock Returns for Turtlemint Fintech Solutions
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.76% | +0.39% | -49.18% | -54.49% | -54.49% | -54.49% |
How will the ₹149.51 crore capital infusion impact Turtlemint Fintech's consolidated cash flow and dividend payout capacity in the upcoming quarters?
What specific growth strategies or product expansions is TIB planning to deploy this capital to sustain its triple-digit revenue acceleration beyond FY26?
Given the high issue price premium, how does this valuation benchmark TIB against other listed insurance intermediaries in the Indian market?


































